JP4960591B2 - Anti-allergen composition containing mannooligosaccharides - Google Patents
Anti-allergen composition containing mannooligosaccharides Download PDFInfo
- Publication number
- JP4960591B2 JP4960591B2 JP2004360681A JP2004360681A JP4960591B2 JP 4960591 B2 JP4960591 B2 JP 4960591B2 JP 2004360681 A JP2004360681 A JP 2004360681A JP 2004360681 A JP2004360681 A JP 2004360681A JP 4960591 B2 JP4960591 B2 JP 4960591B2
- Authority
- JP
- Japan
- Prior art keywords
- mannose
- coffee
- composition
- oligosaccharide
- mainly composed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 68
- 239000013566 allergen Substances 0.000 title description 10
- 229920001542 oligosaccharide Polymers 0.000 claims description 56
- 235000013353 coffee beverage Nutrition 0.000 claims description 48
- 235000016213 coffee Nutrition 0.000 claims description 46
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 43
- 238000000605 extraction Methods 0.000 claims description 21
- 241000533293 Sesbania emerus Species 0.000 claims description 17
- 150000002772 monosaccharides Chemical class 0.000 claims description 17
- 229920000057 Mannan Polymers 0.000 claims description 14
- 230000003301 hydrolyzing effect Effects 0.000 claims description 9
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 9
- 229930182830 galactose Natural products 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 229930091371 Fructose Natural products 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- 230000003266 anti-allergic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 description 47
- 238000000034 method Methods 0.000 description 23
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 235000013305 food Nutrition 0.000 description 15
- 230000000694 effects Effects 0.000 description 11
- 235000013361 beverage Nutrition 0.000 description 10
- 230000007062 hydrolysis Effects 0.000 description 10
- 238000006460 hydrolysis reaction Methods 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 235000021539 instant coffee Nutrition 0.000 description 6
- 239000003456 ion exchange resin Substances 0.000 description 6
- 229920003303 ion-exchange polymer Polymers 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 5
- 239000003014 ion exchange membrane Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 238000005903 acid hydrolysis reaction Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 3
- 244000060011 Cocos nucifera Species 0.000 description 3
- 229920000926 Galactomannan Polymers 0.000 description 3
- 235000006694 eating habits Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- 229920002581 Glucomannan Polymers 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 239000003377 acid catalyst Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 238000004332 deodorization Methods 0.000 description 2
- 229940046240 glucomannan Drugs 0.000 description 2
- 229940059442 hemicellulase Drugs 0.000 description 2
- 108010002430 hemicellulase Proteins 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PZPXDAEZSA-N 4β-mannobiose Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-PZPXDAEZSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241001203952 Feia Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 241000234479 Narcissus Species 0.000 description 1
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- FTNIPWXXIGNQQF-UHFFFAOYSA-N UNPD130147 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(OC4C(OC(O)C(O)C4O)CO)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O FTNIPWXXIGNQQF-UHFFFAOYSA-N 0.000 description 1
- LUEWUZLMQUOBSB-UHFFFAOYSA-N UNPD55895 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(O)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O LUEWUZLMQUOBSB-UHFFFAOYSA-N 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 125000000704 aldohexosyl group Chemical group 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- YETHWGOYCQLNKG-FHERGOJNSA-N alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-D-Manp Chemical compound O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@H]1O[C@@H]1[C@@H](O[C@@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YETHWGOYCQLNKG-FHERGOJNSA-N 0.000 description 1
- LHAOFBCHXGZGOR-NAVBLJQLSA-N alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1 LHAOFBCHXGZGOR-NAVBLJQLSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- LUEWUZLMQUOBSB-MHJOMNRISA-N beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-D-Manp Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3[C@H](OC(O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@@H](O)[C@H]1O LUEWUZLMQUOBSB-MHJOMNRISA-N 0.000 description 1
- OCIBBXPLUVYKCH-KKQGKRJZSA-N beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-D-Manp Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3[C@H](O[C@@H](O[C@@H]4[C@H](O[C@@H](O[C@@H]5[C@H](OC(O)[C@@H](O)[C@H]5O)CO)[C@@H](O)[C@H]4O)CO)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@@H](O)[C@H]1O OCIBBXPLUVYKCH-KKQGKRJZSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- -1 composed of mannose Chemical class 0.000 description 1
- 239000002361 compost Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002440 industrial waste Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 1
- 150000002704 mannoses Chemical class 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
Description
本発明は、マンノースを主体とする構成糖からなるオリゴ糖類を主成分とする抗アレルゲン作用を有する組成物、およびその組成物を用いた経口摂取可能な組成物、特に飲料、食物および飼料に関するものである。また、本発明は未利用資源の有効活用にも関するものである。 TECHNICAL FIELD The present invention relates to a composition having an antiallergenic activity mainly composed of oligosaccharides composed of saccharides mainly composed of mannose, and an orally ingestible composition using the composition, particularly to beverages, foods and feeds. It is. The present invention also relates to effective use of unused resources.
コーヒーの抽出残渣は従来、そのほとんどが焼却あるいは産業廃棄物として処理されてきた。近年になり、コーヒー抽出残渣が堆肥原料あるいは活性炭原料として利用されるようになってきたが、それらは未利用資源の高度利用という観点からは十分とはいえず、更なるコーヒー抽出残渣の高度利用の方法を確立することは重要課題となっている。 Conventionally, most coffee extraction residues have been treated as incineration or industrial waste. In recent years, coffee extraction residues have come to be used as raw materials for compost or activated carbon, but these are not sufficient from the viewpoint of advanced utilization of unused resources. Establishing this method has become an important issue.
さらに、現代においては花粉症やアトピー性皮膚炎などアレルギーに由来すると考えられる疾患が増加の一途をたどっている。アレルギー反応において、IgEが最も重要な役割を担っている抗体として良く知られている。アレルゲンが体内に侵入するとIgEが産生され、肥満細胞上のレセプターと結合する。その結果、ヒスタミン、ロイコトリエン、プロスタグランジンなどの化合物が作り出され、組織の炎症、血管透過性亢進などが引き起こされアレルギー疾患へと繋がっていく。鼻の粘膜に作用するとアレルギー性鼻炎、皮膚で炎症が起こるとアトピー性皮膚炎などの疾患となる。そのため種々の食品中からIgEを低減させる成分の探索やその作用機作についての研究が行われている(特許文献1、2及び3)。各種の健康補助食品が開発・販売されているが、日常の食生活で手軽にそして経済的に抗アレルゲン効果を期待出来る飲食品の開発には至っていない。
本発明は、通常の食生活習慣の大幅な変更を伴うことなく、しかも抗アレルゲン効果に優れ経済的かつ簡便な飲食物を提供することを目的としている。 An object of the present invention is to provide an economical and simple food and drink that is not accompanied by a significant change in normal eating habits and has an excellent anti-allergen effect.
本発明者らは、これらのような課題を解決するために鋭意検討の結果、マンナンを多く含む食品素材、主に、コーヒー抽出粕加水分解物から、糖鎖中にマンノース残基以外の糖残基の含有量が少ない重合度1以上10以下のマンノオリゴ糖類、すなわちマンノースとグルコースおよびガラクトースのような単糖類の少なくとも1種とが1以上10分子以下結合した、マンノースを主体としたオリゴ糖類に抗アレルゲン作用を見いだし、本発明を完成するに至った。さらに、無着色、無酸の糖鎖中にマンノース残基以外の糖残基の含有量が少ない重合度1以上10以下のマンノオリゴ糖類を得ることで、食品への適用範囲を飛躍的に広げることができることを見いだした。 As a result of diligent studies to solve these problems, the present inventors have found that sugar residues other than mannose residues are present in sugar chains from food materials containing a large amount of mannan, mainly coffee extract koji hydrolysates. Anti-mannose oligosaccharides having a low group content and having a degree of polymerization of 1 to 10 (ie, mannose and at least one monosaccharide such as glucose and galactose bonded to 1 to 10 molecules). The allergen action was found and the present invention was completed. Furthermore, by obtaining a mannooligosaccharide having a degree of polymerization of 1 or more and 10 or less with a low content of sugar residues other than mannose residues in a non-colored and acid-free sugar chain, the scope of application to foods is dramatically expanded. I found out that I can do it.
したがって、本発明の態様は、以下の通りである。
1.1以上10分子以下の、マンノースを主体とした単糖類が結合した、マンノースを主体としたオリゴ糖類を含むことを特徴とする、抗アレルゲン性組成物。
2.前記マンノースを主体としたオリゴ糖類が、1以上10分子以下のマンノースが結合したオリゴ糖類であることを特徴とする、上記1に記載の抗アレルゲン性組成物。
3.前記マンノースを主体としたオリゴ糖類が、マンノースと、グルコース、ガラクトース、フルクトースからなる群から選ばれる少なくとも1種の単糖とが、合計で1以上10分子以下結合した、マンノースを主体としたオリゴ糖類であることを特徴とする、上記1に記載の抗アレルゲン性組成物。
4.前記マンノースを主体としたオリゴ糖の含有割合が、組成物中の総固形分に対して60重量%以上である、上記1〜3のいずれか1項に記載の抗アレルゲン性組成物。
5.前記マンノースを主体としたオリゴ糖類中のマンノース残基の割合が、70重量%以上である、上記1〜4のいずれか1つに記載の抗アレルゲン性組成物。
6.前記マンノースを主体としたオリゴ糖類が、分子中のマンノース単位の数が2〜6のオリゴ糖であることを特徴とする、上記1〜5のいずれか1つに記載の抗アレルゲン性組成物。
7.前記マンノースを主体としたオリゴ糖類が、マンナンを加水分解処理することによって得られるものであることを特徴とする、上記1〜6のいずれか1つに記載の抗アレルゲン性組成物。
8.前記マンナンが、コーヒー豆および/またはコーヒー抽出残渣から得られるものである、上記7に記載の抗アレルゲン性組成物。
9.前記マンノースを主体としたオリゴ糖類が、β−1,4−マンノオリゴ糖であることを特徴とする、上記1〜8のいずれか1つに記載の抗アレルゲン性組成物。
10.上記1〜9のいずれか1つに記載の抗アレルゲン性組成物を含有する経口摂取可能な組成物。
11.前記経口摂取可能な組成物が飲料である、上記10に記載の組成物。
12.前記飲料が、液体コーヒー、インスタントコーヒー飲料またはコーヒーミックス飲料である、上記11に記載の組成物。
13.前記経口摂取可能な組成物が食品である、上記10に記載の組成物。
14.前記経口摂取可能な組成物が飼料である、上記10に記載の組成物。
Accordingly, aspects of the present invention are as follows.
1. An antiallergenic composition comprising an oligosaccharide mainly composed of mannose and having a mannose-based monosaccharide bound thereto in an amount of 1.1 to 10 molecules.
2. 2. The antiallergenic composition according to 1 above, wherein the oligosaccharide mainly comprising mannose is an oligosaccharide having 1 to 10 molecules of mannose bound thereto.
3. The oligosaccharide mainly composed of mannose is composed mainly of mannose and at least one monosaccharide selected from the group consisting of glucose, galactose, and fructose in a total of 1 to 10 molecules. 2. The antiallergenic composition according to 1 above, wherein
4). 4. The antiallergenic composition according to any one of 1 to 3 above, wherein the content ratio of the oligosaccharide mainly composed of mannose is 60% by weight or more based on the total solid content in the composition.
5. 5. The antiallergenic composition according to any one of 1 to 4 above, wherein a ratio of a mannose residue in the oligosaccharide mainly composed of mannose is 70% by weight or more.
6). 6. The antiallergenic composition as described in any one of 1 to 5 above, wherein the oligosaccharide mainly composed of mannose is an oligosaccharide having 2 to 6 mannose units in the molecule.
7). The antiallergenic composition according to any one of the above 1 to 6, wherein the oligosaccharide mainly comprising mannose is obtained by hydrolyzing mannan.
8). 8. The antiallergenic composition according to 7 above, wherein the mannan is obtained from coffee beans and / or coffee extraction residue.
9. 9. The antiallergenic composition according to any one of 1 to 8 above, wherein the oligosaccharide mainly composed of mannose is β-1,4-mannooligosaccharide.
10. 10. An orally ingestible composition comprising the antiallergenic composition according to any one of 1 to 9 above.
11. 11. The composition according to 10 above, wherein the orally ingestible composition is a beverage.
12 12. The composition according to 11 above, wherein the beverage is liquid coffee, instant coffee beverage or coffee mixed beverage.
13. 11. The composition according to 10 above, wherein the orally ingestible composition is a food.
14 11. The composition according to 10 above, wherein the orally ingestible composition is a feed.
抗アレルゲン性を有するマンノースを主体としたオリゴ糖類を飲食物に添加することにより、これを日常の食生活で手軽にそして経済的に摂取可能となり、抗アレルゲン効果を期待することが出来る。抗アレルゲン性を有するマンノースを主体としたオリゴ糖類は、コーヒー抽出残渣のような、廃棄物からも入手可能であるため、従来利用されていない資源を有効活用することができる。 By adding an oligosaccharide mainly composed of mannose having antiallergenic properties to food and drink, it can be easily and economically consumed in daily eating habits, and an antiallergenic effect can be expected. Since oligosaccharides mainly composed of mannose having antiallergenic properties can be obtained from wastes such as coffee extraction residues, resources that have not been conventionally used can be effectively utilized.
次に本発明の内容を詳細に説明する。
本発明において「マンノースを主体としたオリゴ糖類」とは、単糖であるマンノースを主たる構成要素とするオリゴ糖類を意味する。ここで「オリゴ糖類」なる語は、一般に単糖類と多糖類との間に位し、一定の少数量の単糖類分子のグリコシル結合からなる物質を指す。すなわち、結合している単糖の数が比較的少ないポリマーのことである。オリゴ糖「類」という場合、構成単糖の数が種々のオリゴ糖が複数含まれる組成物であることを意味する。そしてマンノースを主体としたオリゴ糖「類」という場合は、構成単糖の種類や数が種々のオリゴ糖が複数含まれる組成物を指す。本明細書において「マンノオリゴ糖類」の語は、「マンノースを主体としたオリゴ糖類」の語と同様の意味において用いられる。
Next, the contents of the present invention will be described in detail.
In the present invention, the “oligosaccharide mainly composed of mannose” means an oligosaccharide mainly composed of mannose which is a monosaccharide. Here, the term “oligosaccharide” generally refers to a substance that is located between a monosaccharide and a polysaccharide and consists of a glycosyl bond of a certain minor amount of a monosaccharide molecule. That is, it is a polymer with a relatively small number of monosaccharides bound thereto. The term “oligosaccharide” refers to a composition containing a plurality of oligosaccharides having various constituent monosaccharides. The oligosaccharide “class” mainly composed of mannose refers to a composition containing a plurality of oligosaccharides having various types and numbers of constituent monosaccharides. In the present specification, the term “mannooligosaccharide” is used in the same meaning as the term “oligosaccharide mainly composed of mannose”.
本明細書において、オリゴ糖類の重合度を表すために「DP」と記載することがある。DPとは、オリゴ糖類を構成している単糖の数を意味する。すなわち単糖であるマンノースは「DP1」と表され、4つのマンノースから構成されたマンノオリゴ糖は重合度4、すなわち「DP4」と表される。学術的観点からは、重合度1(DP1)の糖は単糖であって、オリゴ糖ではない。しかし、本発明に用いるオリゴ糖類(組成物)中には、わずかに単糖が含まれる場合があるので、本明細書においてはこのような場合であっても総称して「オリゴ糖類」と呼ぶものとする。すなわち、「1以上10分子以下の、マンノースを主体とした単糖類が結合した、マンノースを主体としたオリゴ糖類」と言う場合には、この糖組成物中には重合度1の単糖も含まれている場合があると理解されたい。 In this specification, “DP” may be used to indicate the degree of polymerization of the oligosaccharide. DP means the number of monosaccharides constituting the oligosaccharide. That is, mannose, which is a monosaccharide, is expressed as “DP1”, and a mannooligosaccharide composed of four mannoses is expressed as a polymerization degree of 4, that is, “DP4”. From an academic point of view, sugars with a degree of polymerization of 1 (DP1) are monosaccharides, not oligosaccharides. However, since the oligosaccharide (composition) used in the present invention may contain a slight amount of monosaccharide, even in such a case, it is generically called “oligosaccharide”. Shall. That is, when it is referred to as “an oligosaccharide mainly composed of mannose having 1 to 10 molecules and mainly composed of mannose”, the saccharide composition also includes a monosaccharide having a polymerization degree of 1. It should be understood that there are cases.
本発明において用いられるマンノースを主体としたオリゴ糖類は、1以上10分子以下の、マンノースを主体とした単糖類が結合した複数種類のオリゴ糖の組成物であることが好ましい。特に好ましいオリゴ糖類は、マンノースが1以上10分子以下結合したオリゴ糖類か、あるいはマンノースと、グルコース、ガラクトース、フルクトースからなる群から選ばれる少なくとも1種の単糖とが、合計で1以上10分子以下結合した、複数種類のオリゴ糖の組成物である。さらに特に好ましくは、β−1,4−マンノオリゴ糖類である。また「マンノースを主体とした」という場合、オリゴ糖類中のマンノース残基の構成割合が70重量%以上であることを指し、特に80重量%以上であることが好ましい。マンノース残基の割合が70%に満たないと、抗アレルゲン性効果が大きく期待できないとともに、甘味度も増し、組成物の適用の幅が狭まる場合がある。 The oligosaccharide mainly composed of mannose used in the present invention is preferably a composition of a plurality of types of oligosaccharides in which 1 to 10 molecules of monosaccharide mainly composed of mannose are bonded. Particularly preferred oligosaccharides are oligosaccharides in which 1 to 10 molecules of mannose are bound, or mannose and at least one monosaccharide selected from the group consisting of glucose, galactose and fructose in total of 1 to 10 molecules in total. It is a composition of multiple types of oligosaccharides linked together. Further particularly preferred are β-1,4-mannooligosaccharides. In addition, the expression “mainly composed of mannose” indicates that the constituent ratio of mannose residues in the oligosaccharide is 70% by weight or more, and particularly preferably 80% by weight or more. If the ratio of mannose residues is less than 70%, the antiallergenic effect cannot be expected greatly, the sweetness level increases, and the range of application of the composition may be narrowed.
また、本発明において用いられるマンノースを主体としたオリゴ糖類は、その分子中のマンノース単位の数が2〜9、特に2〜6であることが好ましい。
本発明の一の態様は、上述のマンノースを主体としたオリゴ糖類を含む、抗アレルゲン性組成物である。ここで「抗アレルゲン性組成物」という語は、広く一般にアレルゲン性作用を有する組成物を意味するが、本明細書では特に体内のIgEを低減させることにより、IgE由来のアレルギー疾患の発生を低減させうる物質を含む混合物を意味する。上述のとおり、本発明者らは、マンノースを主体としたオリゴ糖類が、体内のIgEを低減させる効果を有することを見いだしている。したがって、かかる抗アレルゲン性を有するオリゴ糖類を用いて抗アレルゲン性組成物を製造することができる。
Moreover, it is preferable that the number of the mannose unit in the molecule | numerator of the oligosaccharide mainly composed of mannose used in this invention is 2-9.
One aspect of the present invention is an antiallergenic composition comprising the above-mentioned oligosaccharides mainly composed of mannose. Here, the term “anti-allergenic composition” means a composition having an allergenic action in general, but in this specification, the occurrence of allergic diseases derived from IgE is particularly reduced by reducing IgE in the body. It means a mixture containing substances that can be made to occur. As described above, the present inventors have found that oligosaccharides mainly composed of mannose have an effect of reducing IgE in the body. Therefore, an antiallergenic composition can be produced using such an oligosaccharide having antiallergenic properties.
さて、本発明に用いられるマンノースを主体としたオリゴ糖類は、マンナンを加水分解することにより製造することができる。ここで原料のマンナンは、たとえばココナッツ椰子から得られるコプラミール、フーク、南アフリカ産椰子科植物HuacraPalm、ツクネイモマンナン、ヤマイモマンナンより抽出することにより得ることができる。このように得たマンナンを、酸加水分解、高温加熱加水分解、酵素加水分解、微生物発酵の中から選ばれる1種または2種以上の方法で処理し、好ましくは活性炭処理、吸着樹脂処理、イオン交換樹脂処理、イオン交換膜処理等の方法で精製して、糖混合物を得ることができる。かかる当混合物中には、上述した、抗アレルゲン性のマンノースを主体としたオリゴ糖類が含まれている。したがって、このように得た組成物は、本発明の抗アレルゲン性組成物となる。さらに、本発明の抗アレルゲン性組成物は、コンニャクイモ、ユリ、スイセン、ヒガンバナ等に含まれるグルコマンナン、ローカストビーンガム、グアーガム等に含まれるガラクトマンナンを酸加水分解、高温加熱加水分解、酵素加水分解、微生物発酵の中から選ばれる1種または2種以上の方法で処理し、活性炭処理、吸着樹脂処理、イオン交換樹脂処理、イオン交換膜処理等の方法で分離精製し構成糖としてマンノースの比率を高めることにより製造したものであってもよい。したがって、本明細書において単に「マンナン」という場合は、d−マンノースのみを構成単位とする多糖であるマンナンの他、マンノースとガラクトースまたはグルコースとを構成単位とした多糖であるガラクトマンナン、グルコマンナンも広義に含むものとする。なお、d−マンノースとは、アルドヘキソースであり、d−グルコース中のカルボキシル基に隣接する炭素に結合している水酸基の立体配置が逆になっているものである。 The oligosaccharide mainly composed of mannose used in the present invention can be produced by hydrolyzing mannan. Here, the raw material mannan can be obtained by extraction from, for example, copra meal obtained from coconut coconut, fuchs, South African coconut plants Huacal Palm, tsukunei manmann, and yam mannan. Mannan thus obtained is treated by one or more methods selected from acid hydrolysis, high-temperature heat hydrolysis, enzyme hydrolysis, and microbial fermentation, preferably activated carbon treatment, adsorption resin treatment, ion A sugar mixture can be obtained by purification by a method such as an exchange resin treatment or an ion exchange membrane treatment. This mixture contains the above-mentioned oligosaccharides mainly composed of antiallergenic mannose. Therefore, the composition thus obtained becomes the antiallergenic composition of the present invention. Further, the anti-allergenic composition of the present invention comprises glucomannan, locust bean gum, guar gum and the like galactomannan contained in konjac potato, lily, narcissus, and ganbana, etc., acid hydrolysis, high temperature heating hydrolysis, enzyme hydrolysis. Treated by one or more methods selected from decomposition and microbial fermentation, separated and purified by activated carbon treatment, adsorption resin treatment, ion exchange resin treatment, ion exchange membrane treatment, etc. Ratio of mannose as constituent sugar It may be manufactured by increasing the. Therefore, in the present specification, when “mannan” is simply referred to, mannan which is a polysaccharide having only d-mannose as a constituent unit, galactomannan and glucomannan which are polysaccharides having mannose and galactose or glucose as constituent units are also included. It shall be included in a broad sense. In addition, d-mannose is aldohexose and the configuration of the hydroxyl group bonded to the carbon adjacent to the carboxyl group in d-glucose is reversed.
さらに本発明の抗アレルゲン性組成物は、コーヒー生豆または焙煎したコーヒー豆を酸加水分解、高温加熱加水分解、酵素加水分解、微生物発酵の中から選ばれる1種または2種以上の方法で処理し、活性炭処理、吸着樹脂処理、イオン交換樹脂処理、イオン交換膜処理等の方法で精製することによって得ることができる。あるいは、使用済みコーヒー残渣を、酸加水分解、高温加熱加水分解、酵素加水分解、微生物発酵の中から選ばれる1種または2種以上の方法で可溶化処理した水溶液を活性炭処理、吸着樹脂処理、イオン交換樹脂処理、イオン交換膜処理等の方法で精製することによって得ることも可能である。一般に、焙煎粉砕コーヒーを商業用の抽出器にて抽出すると、その際に焙煎コーヒーに含まれるガラクトマンナンの側鎖であるガラクトースが可溶化したり、アラビノガラクタンが加水分解したりして可溶化する。従って、コーヒー残渣中にはマンナンが豊富であり、しかも直鎖構造をとっているものと推定される。一方、セルロースは分解されにくく残渣として残っているが、セルロースを分解せずにマンナンを特異的に加水分解する条件を適宜選択することにより、マンノースを主体とするオリゴ糖類を得ることができる。 Furthermore, the anti-allergenic composition of the present invention can be obtained by one or more methods selected from acid hydrolysis, high-temperature heat hydrolysis, enzyme hydrolysis, and microbial fermentation of raw coffee beans or roasted coffee beans. It can be obtained by treatment and purification by a method such as activated carbon treatment, adsorption resin treatment, ion exchange resin treatment, ion exchange membrane treatment. Alternatively, an aqueous solution obtained by solubilizing a used coffee residue by one or more methods selected from acid hydrolysis, high-temperature heat hydrolysis, enzyme hydrolysis, and microbial fermentation is activated carbon treatment, adsorption resin treatment, It can also be obtained by purification by a method such as ion exchange resin treatment or ion exchange membrane treatment. Generally, when roasted and ground coffee is extracted with a commercial extractor, galactose, which is a side chain of galactomannan contained in the roasted coffee, is solubilized or arabinogalactan is hydrolyzed. Solubilize. Therefore, it is presumed that the coffee residue is rich in mannan and has a linear structure. On the other hand, although cellulose is hardly decomposed and remains as a residue, an oligosaccharide mainly composed of mannose can be obtained by appropriately selecting conditions for specifically hydrolyzing mannan without decomposing cellulose.
特にコーヒー抽出残渣を分解する方法としては、酸および/または高温により加水分解する方法、酵素により分解する方法、微生物発酵により分解する方法が挙げられるが、これに限定されない。酸および/または高温により加水分解する方法としては特開昭61−96947号、特開平2−200147号等に開示されている。商業用のコーヒー多段式抽出系において出てくる使用済みコーヒー残渣を反応容器中において酸触媒を添加して加水分解することもできるし、酸触媒を添加せずに高温で短時間処理して加水分解することによっても得ることができる。管形栓流反応器を使用するのが便利であるが比較的高温で短時間の反応を行わせるのに向いているものならば、いかなる反応器を使用しても良好な結果が得られる。反応時間と反応温度を調節し、可溶化して加水分解させることによってDP10〜40のマンナンをDP1〜10のマンノオリゴ糖に分解し、その後コーヒー残渣と分離してマンノオリゴ糖類を得ることができる。なお、ここでコーヒー抽出残渣とは、大気中で焙煎粉砕コーヒーを抽出処理した後の、いわゆるコーヒー抽出粕のことである。 Examples of the method for decomposing the coffee extraction residue include, but are not limited to, a method of hydrolyzing with an acid and / or high temperature, a method of decomposing with an enzyme, and a method of decomposing by microbial fermentation. Methods for hydrolyzing with an acid and / or high temperature are disclosed in JP-A Nos. 61-96947 and 2-200147. It is possible to hydrolyze spent coffee residue that comes out in a commercial coffee multistage extraction system by adding an acid catalyst in a reaction vessel or by treating it at a high temperature for a short time without adding an acid catalyst. It can also be obtained by decomposing. Although it is convenient to use a tubular plug flow reactor, good results can be obtained with any reactor that is suitable for carrying out a reaction at a relatively high temperature for a short time. Mannanoligosaccharides of DP10-40 are decomposed into DP1-10 manno-oligosaccharides by adjusting the reaction time and reaction temperature, solubilizing and hydrolyzing, and then separating from the coffee residue to obtain manno-oligosaccharides. Here, the coffee extraction residue is a so-called coffee extraction cake after the roasted and ground coffee is extracted in the atmosphere.
本発明の抗アレルゲン性組成物を、コーヒー豆(焙煎コーヒー豆、及び焙煎粉砕コーヒー豆を含む)及び/又はコーヒー抽出残渣の加水分解処理により得る場合、使用するコーヒー豆の種類や産地に特に制限はなく、アラビカ種、ロブスタ種、リベリカ種等いずれのコーヒー豆でもよく、さらにブラジル、コロンビア産等いずれの産地のコーヒー豆も使用することができ、一種類の豆のみを単独で使用しても、ブレンドした二種以上の豆を使用しても良い。通常、商品価値がないとして廃棄処分されるような品質の悪いコーヒー豆または小粒のコーヒー豆であっても使用することができる。上記コーヒー豆を一般的に用いられている焙煎機(直下・熱風・遠赤・炭火式など)により極浅炒り、浅炒り、中炒り、深炒りに焙煎した焙煎コーヒー豆、及びこの焙煎コーヒー豆を、一般的な粉砕器、ミル(グラインディングミル、カッティングミル、ミキサーミル、ロールミルなど)等を用いて粉砕することにより得た、焙煎粉砕コーヒー(粗挽き、中粗挽き、中挽き、中細挽き、細挽きなどの種々の形状のものを含む)を用いることができる。 When the anti-allergenic composition of the present invention is obtained by hydrolysis of coffee beans (including roasted coffee beans and roasted and ground coffee beans) and / or coffee extraction residues, the type and production area of the coffee beans used There is no particular limitation, and any coffee beans such as Arabica, Robusta, and Riberica can be used, and coffee beans from any locality such as Brazil and Colombia can be used, and only one kind of bean is used alone. Alternatively, two or more kinds of blended beans may be used. Usually, even poor quality coffee beans or small coffee beans that are discarded as having no commercial value can be used. Roasted coffee beans roasted in a shallow roast, shallow roast, medium roast, deep roast by a roasting machine (directly, hot air, far-red, charcoal fire, etc.) generally used for the above coffee beans, and this Roasted coffee beans obtained by pulverizing roasted coffee beans using a general pulverizer, mill (grinding mill, cutting mill, mixer mill, roll mill, etc.), etc. Including various shapes such as medium grind, medium fine grind, and fine grind).
また、コーヒー抽出残渣は、通常の液体コーヒーあるいはインスタントコーヒー製造工程において、焙煎粉砕コーヒーを抽出処理した後のものであれば、常圧下、加圧下抽出であろうと、またいかなる起源、製法のコーヒー抽出残渣であっても使用することができる。 In addition, the coffee extraction residue may be extracted under normal pressure or under pressure as long as it is extracted after roasted and ground coffee in a normal liquid coffee or instant coffee manufacturing process, and coffee of any origin and process. Even extraction residues can be used.
ここで、上記加水分解処理について、いくつか詳細に説明する。酵素により分解する方法としては、たとえばコーヒー抽出残渣を水性媒体に懸濁させ、ここへたとえば市販のセルラーゼおよびヘミセルラーゼ等を加えて撹拌しながら懸濁させればよい。酵素の量、作用させる温度およびその他の条件としては、通常の酵素反応に用いられる量、温度、条件であればとくに問題はなく、使用する酵素の最適作用量、温度、条件およびその他の要因によって適宜選択すればよい。 Here, some of the hydrolysis treatments will be described in detail. As a method of decomposing with an enzyme, for example, a coffee extraction residue may be suspended in an aqueous medium, and then commercially available cellulase, hemicellulase, etc. may be added thereto and suspended with stirring. There are no particular problems with the amount of enzyme, the temperature at which it acts, and other conditions as long as it is the amount, temperature, and conditions used in normal enzyme reactions, depending on the optimum amount of enzyme used, temperature, conditions, and other factors. What is necessary is just to select suitably.
微生物発酵により分解する方法としては、たとえば水性媒体に懸濁させたコーヒー抽出残渣にセルラーゼ、ヘミセルラーゼなどを産出する微生物を植菌して培養させればよい。使用する微生物は、細菌類や担子菌類などコーヒー抽出残渣中のマンナンを分解する酵素を産出するものであれば良く、使用する微生物によって培養条件などは適宜選択すればよい。 As a method of decomposing by microbial fermentation, for example, a microorganism that produces cellulase, hemicellulase, etc. may be inoculated and cultured in a coffee extraction residue suspended in an aqueous medium. The microorganism to be used may be any microorganism that produces an enzyme that decomposes mannan in the coffee extraction residue such as bacteria and basidiomycetes, and the culture conditions and the like may be appropriately selected depending on the microorganism to be used.
上記の方法によって得られたマンノースを主体とするオリゴ糖類を含む抗アレルゲン性組成物を含む反応液は、必要に応じて精製を行うことができる。精製法としては、骨炭、活性炭、炭酸飽充法、吸着樹脂、マグネシア法、溶剤抽出法等で脱色・脱臭を行い、イオン交換樹脂、イオン交換膜、電気透析等で脱塩、脱酸を行うことが挙げられる。精製法の組み合わせおよび精製条件としては、マンノースを主体としたオリゴ糖類を含む反応液中の色素、塩、および酸等の量およびその他の要因に応じて適宜選択すればよい。 The reaction solution containing the antiallergenic composition containing the oligosaccharide mainly composed of mannose obtained by the above method can be purified as necessary. As purification methods, bone charcoal, activated carbon, carbonic acid saturation method, adsorption resin, magnesia method, solvent extraction method, etc. are used for decolorization and deodorization, and ion exchange resin, ion exchange membrane, electrodialysis, etc. are used for desalting and deoxidation. Can be mentioned. The combination of the purification methods and the purification conditions may be appropriately selected according to the amount of the dye, salt, acid, etc. in the reaction solution containing the oligosaccharide mainly composed of mannose and other factors.
また、本発明は、上記に説明した本発明に係る抗アレルゲン性組成物を含有する経口摂取可能な組成物、特に飲料、食物および飼料にも関する。さらに、本発明の抗アレルゲン性組成物は、上記飲食物、飼料のみならず、化粧品、医薬品等幅広い分野で使用することも可能である。本発明の抗アレルゲン性組成物は、特に飲食物として人が口から摂取することにより抗アレルゲン性効果を発揮する。 The present invention also relates to an orally ingestible composition containing the antiallergenic composition according to the present invention described above, particularly beverages, foods and feeds. Furthermore, the anti-allergenic composition of the present invention can be used in a wide range of fields such as cosmetics and pharmaceuticals as well as the above-mentioned food and drink and feed. The anti-allergenic composition of the present invention exhibits an anti-allergenic effect when a person ingests it as a food or drink from the mouth.
例えば、コーヒー抽出残渣を酸および/または熱により加水分解しオリゴ糖類を高純度に含むように調製した抗アレルゲン性組成物を液体コーヒー、インスタントコーヒー等にそのまま添加して使用することができる。必要に応じて活性炭、イオン交換樹脂、溶剤等で脱色、脱臭、脱酸等の精製処理をした組成物を添加した方が、コーヒー本来の味、香りのより豊かなコーヒーを提供することができる。ここで、液体コーヒーとしては、一般にレギュラーコーヒーと呼ばれるものが挙げられ、インスタントコーヒーとしては、可溶性粉末コーヒーを水に溶解した可溶性粉末コーヒー飲料や、可溶性粉末コーヒーに砂糖、クリーミングパウダーなどを添加して製造したコーヒーミックス飲料などが挙げられる。 For example, an anti-allergenic composition prepared by hydrolyzing a coffee extraction residue with acid and / or heat to contain an oligosaccharide with high purity can be used as it is added to liquid coffee, instant coffee or the like. If necessary, adding a composition that has been purified by decolorization, deodorization, deoxidation, etc. with activated carbon, ion exchange resin, solvent, etc. can provide coffee with a richer flavor and aroma. . Here, liquid coffee includes what is generally called regular coffee, and instant coffee includes soluble powdered coffee beverages in which soluble powdered coffee is dissolved in water, and sugar and creaming powder added to soluble powdered coffee. The coffee mix drink etc. which were manufactured are mentioned.
(発明の効果)
本発明の抗アレルゲン性組成物を含む飲食物を日常的に摂取することにより、前記体内のIgEレベルを低下させ、もって抗アレルゲン作用の発現を期待することができる。
(The invention's effect)
By daily intake of food and drink containing the anti-allergenic composition of the present invention, it is possible to reduce the IgE level in the body and thus to exhibit the anti-allergen action.
本発明の抗アレルゲン性組成物、およびこれを含むコーヒーミックス飲料を以下のように調製し、この飲料の抗アレルゲン効果を調べた。本実施例は本発明の実施の態様を具体的に説明したものであって、本発明の範囲を限定することを意図しない。
実施例1
マンノオリゴ糖の調製
常法により得た焙煎粉砕コーヒーを、商業上使用されるパーコレーション系にて抽出し、後に残ったコーヒー抽出残渣を得た。このコーヒー抽出残渣を反応器に送りやすくするために、まず粉砕して粒径を約1mmにした。次いで、水と、この粉砕物からなる総固形分濃度約14w/w%のスラリーを調製し、4mの熱栓流反応器内において熱処理した。滞留時間8分に対応する速度で高圧蒸気とともに栓流反応器にポンプ輸送し、6.35mmφオリフィスを用いて約210℃に維持した。その後、大気圧下に噴出することによって、反応を急止した。できたスラリーを濾過して、不溶性固形分から可溶性固形分を含む液を分離した。この可溶性固形分含有液を活性炭、吸着樹脂で脱色し、さらにイオン交換樹脂で脱塩した後、濃縮、乾燥してマンノースを主体とするオリゴ糖類を含有する組成物を収率14%で得た。
The anti-allergenic composition of the present invention and a coffee mix beverage containing the same were prepared as follows, and the anti-allergen effect of this beverage was examined. This example specifically describes the embodiment of the present invention, and is not intended to limit the scope of the present invention.
Example 1
Preparation of Manno-oligosaccharide Roasted and ground coffee obtained by a conventional method was extracted by a commercially used percolation system to obtain a residual coffee extraction residue. In order to make it easy to send this coffee extraction residue to the reactor, it was first pulverized to a particle size of about 1 mm. Next, a slurry having a total solid concentration of about 14 w / w% composed of water and the pulverized product was prepared and heat-treated in a 4 m hot plug flow reactor. Pumped to a plug flow reactor with high pressure steam at a rate corresponding to a residence time of 8 minutes and maintained at about 2 10 ° C using a 6.35 mmφ orifice. Thereafter, the reaction was stopped by spraying under atmospheric pressure. The resulting slurry was filtered to separate a liquid containing soluble solids from insoluble solids. This soluble solid-containing liquid was decolorized with activated carbon and an adsorption resin, further desalted with an ion exchange resin, concentrated and dried to obtain a composition containing oligosaccharides mainly composed of mannose at a yield of 14%. .
このようにして得られた抗アレルゲン作用を有する組成物中に含まれるオリゴ糖類のDP分布は、DP1;2.4%、DP2;26.6%、DP3;20.2%、DP4;17.8%、DP5;10.9%、DP6;8.9%、DP7;6.0%、DP8;3.6%、DP9;1.9%、DP10;1.7%で、糖鎖中のマンノース残基の含有量は90%であった。オリゴ糖のDP1としてはマンノース等、DP2としてはマンノビオース等、DP3としてはマンノトリオース等、DP4としてはマンノテトラオース等、DP5としてはマンノペンタオース等、DP6としてはマンノヘキサオース等、DP7としてはマンノヘプタオース等、DP8としてはマンノオクタオース等、DP9としてはマンノノナオース等、DP10としてはマンノデカオース等で、結合様式はβ−1,4結合である。このようにして得たマンノオリゴ糖類を用いて以下の抗アレルゲン実験を行った。
IgE測定用コーヒーミックスの調製
マンノオリゴ糖類を含む組成物3gにインスタントコーヒー(味の素ゼネラルフーヅ(株)、商品名:ブレンディ)1.5g、クリーミングパウダー(味の素ゼネラルフーヅ(株)、商品名:マリーム)3gおよび砂糖(新三井製糖(株)、商品名:グラニュー糖)5gとを混合してコーヒーミックスを調製したこのミックスをお湯150mLで溶かし、官能評価した結果、従来のインスタントコーヒーの味を十分維持し、しかも、より濃厚で味わい深いコーヒー飲料であった。
コーヒーミックスのIgE抑制効果
12人の被験者が、前記コーヒーミックス12.5gをお湯150mLで溶かして毎日一杯ずつ4週間連続摂取した。摂取開始日及び摂取4週間後に採血した。血清中のIgEをFEIA法にて測定した。結果を以下の表1に示す。マンノオリゴ糖類を含むコーヒーミックス飲料の摂取により血液中のIgEが有意に低下することを確認した。この結果よりマンノオリゴ糖を含む食品を摂取することにより日常の食習慣を変えることなく抗アレルギー効果が期待できる。
The DP distribution of the oligosaccharides contained in the anti-allergenic composition thus obtained is as follows: DP1; 2.4%, DP2; 26.6%, DP3; 20.2%, DP4; 8%, DP5; 10.9%, DP6; 8.9%, DP7; 6.0%, DP8; 3.6%, DP9; 1.9%, DP10; 1.7% The content of mannose residues was 90%. Oligosaccharide DP1 as mannose, DP2 as mannobiose, DP3 as mannotriose, DP4 as mannotetraose, DP5 as mannopentaose, DP6 as mannohexaose, etc. DP7 is mannoheptaose or the like, DP8 is mannooctaose or the like, DP9 is mannononaose or the like, DP10 is mannodekaose or the like, and the binding mode is β-1,4 bond. The following anti-allergen experiment was conducted using the manno-oligosaccharide thus obtained.
Preparation of a coffee mix for measuring IgE 3 g of a composition containing manno-oligosaccharides, 1.5 g of instant coffee (Ajinomoto General Foods Co., Ltd., trade name: Brendi), 3 g of creaming powder (Ajinomoto General Foods Co., Ltd., trade name: Marime) and sugar (Shin-Mitsui Sugar Co., Ltd., trade name: granulated sugar) mixed with 5g to prepare a coffee mix, dissolved in 150mL of hot water, and sensory evaluation. As a result, the taste of conventional instant coffee was sufficiently maintained. It was a richer and more delicious coffee drink.
IgE inhibitory effect of coffee mix Twelve subjects took 12.5 g of the coffee mix in 150 mL of hot water and ingested one cup every day for 4 weeks. Blood was collected on the day of ingestion and 4 weeks after ingestion. IgE in serum was measured by the FEIA method. The results are shown in Table 1 below. It was confirmed that the ingestion of the coffee mix beverage containing mannooligosaccharide significantly reduced IgE in blood. From these results, anti-allergic effects can be expected by ingesting foods containing mannooligosaccharides without changing daily eating habits.
本発明の抗アレルゲン性組成物は、抗アレルゲン性を有するマンノースを主体としたオリゴ糖類を含み、具体的にはマンナンを加水分解することにより製造することができる。本発明の抗アレルゲン性組成物を飲食物、飼料などに添加して日常的に摂取することによって、抗アレルゲン効果を期待できる。本発明の抗アレルゲン性組成物の原料として、例えばコーヒー豆やコーヒー抽出残渣を利用することができる。すなわち、従来は廃棄物として処理されていたコーヒー抽出残渣から抗アレルゲン効果のある組成物を調製し、これを飲食物などと共に摂取することが可能となるため、健康改善効果に加えて廃棄資源の再利用という観点からも非常に有用な発明である。 The anti-allergenic composition of the present invention contains an oligosaccharide mainly composed of mannose having anti-allergenic properties, and can specifically be produced by hydrolyzing mannan. The anti-allergen effect can be expected by adding the anti-allergenic composition of the present invention to foods and drinks, feeds, etc. and taking it on a daily basis. As a raw material of the anti-allergenic composition of the present invention, for example, coffee beans or coffee extraction residues can be used. That is, a composition having an anti-allergen effect can be prepared from coffee extraction residue that has been treated as waste and can be ingested together with food and drink. This is a very useful invention from the viewpoint of reuse.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004360681A JP4960591B2 (en) | 2004-12-14 | 2004-12-14 | Anti-allergen composition containing mannooligosaccharides |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004360681A JP4960591B2 (en) | 2004-12-14 | 2004-12-14 | Anti-allergen composition containing mannooligosaccharides |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006169135A JP2006169135A (en) | 2006-06-29 |
JP4960591B2 true JP4960591B2 (en) | 2012-06-27 |
Family
ID=36670266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004360681A Active JP4960591B2 (en) | 2004-12-14 | 2004-12-14 | Anti-allergen composition containing mannooligosaccharides |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4960591B2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5169827B2 (en) * | 2006-06-26 | 2013-03-27 | 不二製油株式会社 | Antiallergic composition and agent, food and drink containing these, and feed |
WO2010109626A1 (en) | 2009-03-26 | 2010-09-30 | 味の素ゼネラルフーヅ株式会社 | Pharmaceutical composition for prevention or treatment of lifestyle-related diseases and food useful therefor |
JP6287479B2 (en) * | 2014-03-28 | 2018-03-07 | 味の素株式会社 | Anticancer drug |
JP6418310B2 (en) * | 2017-11-22 | 2018-11-07 | 味の素株式会社 | Mannopolyosyl fructose production method, oligosaccharide composition, and microorganism culture medium |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6130594A (en) * | 1984-07-21 | 1986-02-12 | Sunstar Inc | Antiallergic |
JP3227214B2 (en) * | 1992-07-15 | 2001-11-12 | 天野エンザイム株式会社 | Flavor improving agent, flavor improving food and drink, and method for producing the food and drink |
JPH06183992A (en) * | 1992-09-04 | 1994-07-05 | Koichi Tateishi | Substance having antiallergic action and its production |
JPH07143849A (en) * | 1993-11-22 | 1995-06-06 | Unie Kafue:Kk | Fried coffee bean chip, its production and mixed food of fried coffee bean chip with other foods |
JPH0873487A (en) * | 1994-09-05 | 1996-03-19 | Nippon High Potsukusu:Kk | Alpha-d-phenyl glycoside derivative |
GB9524752D0 (en) * | 1995-12-04 | 1996-02-07 | Danisco | Modification process |
JP3695855B2 (en) * | 1996-07-22 | 2005-09-14 | 森永製菓株式会社 | A method for producing seasoned processed foods using beans for liquor. |
JP2000316519A (en) * | 1999-05-13 | 2000-11-21 | Unitika Ltd | Flavor-improving agent, and food and beverage improved with flavor by the same |
JP3553866B2 (en) * | 1999-09-14 | 2004-08-11 | 味の素ゼネラルフーヅ株式会社 | Composition based on mannooligosaccharides |
JP2004159659A (en) * | 1999-09-14 | 2004-06-10 | Ajinomoto General Foods Inc | Composition mainly composed of mannooligosaccharide |
JP4684440B2 (en) * | 2001-03-13 | 2011-05-18 | 味の素ゼネラルフーヅ株式会社 | Lipid peroxide elevation-suppressing composition containing mannooligosaccharide |
JP2002262827A (en) * | 2001-03-13 | 2002-09-17 | Ajinomoto General Foods Inc | Serum lipid improving composition containing mannooligosaccharide |
JP3515078B2 (en) * | 2001-03-15 | 2004-04-05 | 味の素ゼネラルフーヅ株式会社 | Taste improvement of food and drink by coffee oligosaccharide |
JP2002306093A (en) * | 2001-04-17 | 2002-10-22 | Ajinomoto General Foods Inc | Promoting composition including mannooligosaccharide for mineral absorption |
JP2002000180A (en) * | 2001-05-14 | 2002-01-08 | Amano Enzyme Inc | Coffee flavor modifier, flavor modified coffee and method for producing the same |
JP4307800B2 (en) * | 2002-07-23 | 2009-08-05 | 味の素ゼネラルフーヅ株式会社 | Immunostimulating composition containing mannooligosaccharide |
JP4369098B2 (en) * | 2002-07-31 | 2009-11-18 | 株式会社ミツカングループ本社 | Allergy-suppressing composition |
JP4675033B2 (en) * | 2003-08-21 | 2011-04-20 | 広島県 | Platelet aggregation inhibitor and histamine release inhibitor |
JP2005289954A (en) * | 2004-03-31 | 2005-10-20 | Cci Corp | Antiallergic substance, method for producing the same, antiallergic agent and food comprising the same as active ingredient |
JP4488852B2 (en) * | 2004-09-17 | 2010-06-23 | 味の素ゼネラルフーヅ株式会社 | Composition having body fat reducing action |
-
2004
- 2004-12-14 JP JP2004360681A patent/JP4960591B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2006169135A (en) | 2006-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4771882B2 (en) | Composition having action of treating, preventing or ameliorating diabetes or diabetic complication and beverage containing the same | |
JP4488852B2 (en) | Composition having body fat reducing action | |
JP5214978B2 (en) | Composition having blood pressure lowering action and / or elevation suppressing action and food and drink containing the same | |
JP3553866B2 (en) | Composition based on mannooligosaccharides | |
JP2002262827A (en) | Serum lipid improving composition containing mannooligosaccharide | |
JP2004159659A (en) | Composition mainly composed of mannooligosaccharide | |
JP4307800B2 (en) | Immunostimulating composition containing mannooligosaccharide | |
JP4684440B2 (en) | Lipid peroxide elevation-suppressing composition containing mannooligosaccharide | |
JP4960591B2 (en) | Anti-allergen composition containing mannooligosaccharides | |
JP6287479B2 (en) | Anticancer drug | |
JP5702713B2 (en) | Pharmaceutical composition for promoting adiponectin production and food useful therefor | |
JP3515078B2 (en) | Taste improvement of food and drink by coffee oligosaccharide | |
JP4851215B2 (en) | Mineral absorption promoting composition containing mannooligosaccharide | |
JP4673753B2 (en) | Serum lipid improving agent containing mannooligosaccharide | |
JP2009275047A (en) | Composition having body fat reducing action and food and drink containing the same | |
JP6269251B2 (en) | Skin quality improver | |
JP6303714B2 (en) | DNA damage inhibitor and method for producing the same | |
JP6418310B2 (en) | Mannopolyosyl fructose production method, oligosaccharide composition, and microorganism culture medium | |
JP2002306093A (en) | Promoting composition including mannooligosaccharide for mineral absorption | |
JP2011140516A (en) | Composition having function of treating, preventing or ameliorating diabetes or diabetic complication, and drink containing the same | |
JP2015189747A (en) | Inhibitors of diacylglycerol acyltransferase and inhibitors of fatty liver | |
CN104825475A (en) | Composition with blood pressure decreasing effect and/or blood pressure increase suppressing effect and drink or food with composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070620 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101108 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110808 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110831 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111108 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20111124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120209 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120224 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120323 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150330 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4960591 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313114 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |